NEWS & EVENTS
May 24, 2021
Michigan Medicine Laboratories Continues to Offer Rapid, Reliable COVID-19 Testing, Opening New Testing Location at I-94 and State Street
Michigan Medicine Laboratories, the reference laboratory division of Michigan Medicine, continues to serve the community with flexible options for fast, high-quality COVID-19 testing, including a convenient new testing location.
April 14, 2021
The North Carolina Society of Pathologist (NCSP) is having their annual 2021 meeting virtually this year. With this year's focus on pulmonary pathology, Dr. Jeffrey Myers was invited to be the key note speaker.
March 12, 2021
Join us in recognizing patient safety awareness week by reviewing our critical values policy. Download our flyer that shows the importance of critical values and how they can affect the lives of patients. And finally, if you are a client and looking for an instructional video for the critical values survey, please find that video link below.
Featured Test (NEW)
PD-L1 Testing for Breast Cancer
Now offering PD-L1 testing using SP142, the FDA-approved companion diagnostic for TECENTRIQ in mTNBC. FDA-approval to evaluate triple-negative breast cancer patients, VENTANA PD-L1 (SP142) Assay uses immune cell staining and scoring within the tumor microenvironment.
Featured Test (NEW)
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.